Oncology

Study finds textured breast implants do not increase the risk of anaplastic large-cell lymphoma, which has grown in incidence since 2008.

Tumor microenvironment differences in Black women may explain disparities in outcomes for those with residual tumors after chemotherapy treatment for ER–positive/HER2-negative breast cancer.

Breast cancer expert joined a panel to discuss aromatase inhibitors at the San Antonio Breast Cancer Symposium (SABCS) on December 6, 2022.

Future research should investigate which therapies with new mechanisms of action add incremental benefit to existing treatment regimens for non-small cell lung cancer.

When used with chemotherapy, pembrolizumab provides a synergistic response to increase survival rates.

Phase 3 monarchE trial assesses distant relapse free-survival, invasive disease-free survival, and overall survival for the treatment of HR-positive/HER2-negative-, node-positive, high-risk early breast cancer.

RxPonder clinical trial results indicate that racial disparities continue to be a major health care challenge.

PHP shows promise extending survival in patients with inoperable intrahepatic cholangiocarinomas or extrahepatic cholangiocarinoma with liver metastases.

Results of RIGHT Choice phase 2 clinical trial show Kisqali doubled PFS and showed fewer adverse events.

Biomarker testing and management of immune-related adverse events are key roles for pharmacists.

A recent study did not find a significant association between a healthy plant-based diet and the risk for colorectal cancer among 93,475 US women.

Three key opportunities for oncology stewardship are dose rounding, implementation of biosimilars, and management of sites of care.

Scott Soefje, director of Pharmacy Cancer Care and assistant professor of Pharmacy at Mayo Clinic, discusses the role of PD-1 inhibitors in treating non–small cell lung cancer.

The allogeneic CAR-T cell therapy is in development for relapsed or refractory large B cell lymphoma and relapsed or refractory B cell non-Hodgkin lymphoma.

Nearly 8 out of 10 individuals within the recommended age range for colorectal cancer screening are considered to have an average risk for the disease.

Pharmacy Times® will be onsite in Texas providing written and video content for the SABCS, which takes place December 6 to 10.

Olutasidenib (Rezlidhia) is indicated for adult patients with relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation detected by an FDA-approved test.

A focus on developing positive connectivity among colleagues may help support hematology/oncology pharmacists’ efforts to advocate for roles that optimize their personal and institutional value.

Patient selection is a key factor in the safe and effective administration of advanced pain management modalities.

Data suggest that few US adults are aware that wine can increase the risk of cancer.

The investigational drug is a monoclonal antibody with a high affinity and specificity for cancer-specific plectin, a cell surface protein that correlates with aggressive tumors and poor prognosis.

Data from the fourth interim analysis of the ARC-7 trial shows that a combination of Fc-silent anti-TIGIT and anti-PD-1 molecules are effective for objective response rates in certain lung cancers.

DeepTCR system showed efficacy as a predictive clinical tool and provided information on the biological mechanisms that underlie how patients respond to immunotherapy.

Looking to 2023, there remain significant opportunities on the road ahead to improve patient outcomes and patient-centered oncology treatment and care.

An experimental drug could help scientists understand the development of mantle cell lymphoma and potentially increase overall survival.

Data to be presented at the 45th Annual San Antonio Breast Cancer Symposium suggest that the novel sequencing test can detect signs of disease recurrence across breast cancer subtypes, improving outcomes.

Treatment with immune checkpoint inhibitors have the potential for immune-related adverse events, such as psoriasis.

Zanubrutinib expressed better cardiac safety measures, higher progression-free survival, and lower discontinuation rates in the ALPINE trial compared with compared ibrutinib.

Derazantinib is an investigational oral inhibitor of FGFR1, FGFR2, and FGFR3 in patients with locally advanced or metastatic intrahepatic cholangiocarcinoma.

Study suggests that high levels of nicotinamide riboside could increase the risk of developing triple-negative breast cancer and may cause the cancer to metastasize to the brain.